Home » Newsletters » BioWorld Science

BioWorld Science

May 10, 2019

View Archived Issues

CRISPR: Efficient editing and efficient inhibition

Gilead and Goldfinch Bio enter strategic collaboration to develop novel therapies for kidney disease

Imidazopyridines targeting methionyl-tRNA synthetase for the treatment of Cryptosporidium infection

Phase II results on ribaxamase to prevent C. difficile infection in beta-lactam-treated patients

New mouse model identifies MYC role in the tumorigenesis of group 3 medulloblastoma

First patient treated in phase I study MCLA-145 for the treatment of advanced solid tumors

Dosing begins in phase IIa PANASH study of liver stem cell therapy in late-stage NASH

CheckMate498 phase III study of Opdivo does not meet primary endpoint

resTORbio initiates phase III program of RTB-101 in clinically symptomatic respiratory illness

Nintedanib ophthalmic nanosuspension tested in animal model as pterygium treatment

First clinical results on K-0706 presented as potential treatment for Parkinson's disease

CAR T-cell therapy targeting AMHR2, a potential treatment for ovarian cancer

Bristol-Myers Squibb presents new hSTING agonists

Incyte patents PI3Kgamma inhibitors

Epizyme discloses EHMT1 and/or EHMT2 inhibitors

eFFECTOR Therapeutics describes MNK1 and MNK2 inhibitors

Tempest Therapeutics divulges IDO1 inhibitors

New phase I trial explores Precigen's PRGN-3005 UltraCAR-T cells for advanced ovarian cancer

Aptose begins phase Ia/Ib study of CG-806 in CLL, SLL and NHL

Mustang announces new phase I trial of CAR T-cell therapy for multiple myeloma

BioCryst completes phase I study of intravenous galidesivir in healthy subjects

Pooled safety analyses of global roxadustat phase III program confirm CV safety

Liver chats with fat via serum protein GPNMB

Urinary NT-proBNP a pulmonary hypertension marker in preterm infants with bronchopulmonary dysplasia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...